The Ru-106 applicator consists of a radioactive core of Ru-106 encapsulated within pure silver as a radiation shield. During surgical insertion, stainless steel suture needles and forceps can occasionally scratch the applicator's silver eyelets and scatter microscopic particles of elemental silver into the operative field. These particles were likely deposited within the subconjunctival tissues of these patients during brachytherapy administration, leading to localised ocular argyrosis. Iatrogenic ocular argyrosis should be considered in the differential diagnosis of new pigmented lesions in patients treated with Ru-106 brachytherapy. This study is the first to unequivocally identify the cause of some post-brachytherapy ocular surface pigmentation as caused by silver.
Keyphrases
- high dose
- gold nanoparticles
- radiation therapy
- silver nanoparticles
- locally advanced
- end stage renal disease
- optic nerve
- low dose
- ejection fraction
- newly diagnosed
- chronic kidney disease
- gene expression
- peritoneal dialysis
- squamous cell carcinoma
- prognostic factors
- radiation induced
- optical coherence tomography
- combination therapy
- smoking cessation
- basal cell carcinoma